PK Modelling and Simulation to Predict Clinical PD Endpoints
Posted on Fri, Oct 14, 2011 @ 04:40 AM
Leading academics and delegates from around the world gathered last week at our exclusive Autumn Seminar, which covered a wide range of topics in latest approaches of the use of PK, PD and PK/PD modelling in drug development. Over 60 delegates from the pharmaceutical industry met to hear a series of presentations and take part in lively debate with key academics and industry thought-leaders.
Applications of PK/PD modelling
Presentations included a keynote review from Professor Bernd Meibohm, University of Tennessee, who examined “Applications of PK/PD modelling in the development of protein therapeutics”; and Professor Alasdair MacGowan’s review entitled “Applications of PK/PD modelling in the development of antimicrobials”. Prof. Meibohm wrapped up the day by chairing a dynamic panel discussion.
PK Modelling and Simulation
Andy Davis, Senior Pharmacokineticist for Bioanalytical Sciences at Quotient Bioresearch talked about "Using PK Modelling and Simulation to Predict Clinical PD Endpoints" and started a lively discussion amongst delegates. He used a case study to highlight the strategy used when modelling concentration data and simulating dosing regimens.
Delegates engaged in a varied programme which featured a series of talks illustrating how modelling can help to make key decisions in drug development with discussion topics covering all stages of development, and small molecules through to biopharmaceuticals. The talks sparked interesting discussion between delegates and guest speakers, and we look forward to the continued success of our annual seminar.